Trial
NCT06524739
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
CSL Behring
Collaborators
—
Condition
Post-COVID Postural Orthostatic Tachycardia Syndrome
Intervention
IgPro20
Why stopped
Sponsor decision, not for safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-13